clinical trial · NCT07313176
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
Britannia Pharmaceuticals Ltd.·—·recruiting·n = 215
Advanced Parkinson DiseaseNo Intervention
brief summary
The primary objective of the study is to assess the effectiveness of LECIGON® treatment on the reduction in OFF time (h/day) from baseline at 12 months as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part IV (MDS-UPDRS IV).
started
May 8, 2026
primary completion
Oct 1, 2028
completion
Jan 1, 2029
last updated
Jun 8, 2026
official title
A Prospective, Non-Interventional Study on the Long-term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIGON®) in Patients With Parkinson's Disease Previously Treated With Subcutaneous Foslevodopa in Routine Care
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol